Patent ID: 8609651
Filing Date: 2013-12-17
Classification: A61K,A61P

Abstract:
1. A pharmaceutical composition for transmucosal administration to a mammal, comprising a solvent system consisting essentially of a first solvent in which benzodiazepine is soluble, wherein the first solvent is composed of one or more components selected from the group consisting of diethyleneglycol monoethylether and tetrahydrofurfuryl alcohol polyethyleneglycol ether, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which benzodiazepine is less soluble than in the first solvent, wherein the second solvent is composed of one or more components selected from the group consisting of glycerol triacetate and propylene glycol, and 10% (weight/weight) or less of an aqueous buffer solution, with the caveat that the solvent system does not comprise free polyethylene glycol polymers; and a therapeutically effective amount of a benzodiazepine; the composition being a single phase and homogeneous liquid composition; and, wherein the composition is formulated to have a viscosity of less than about 32 cP at temperatures between 20-25° C.